Private company
MILLENNIUM MANAGEMENT LLC
American company, incorporated in Delaware. Summary from the record
Last updated Oct 21, 2026.
Overview
- HeadquartersDE1
Corporate structure
MILLENNIUM MANAGEMENT LLC sits at the top of its group. 301 entities, 10 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of MILLENNIUM MANAGEMENT LLC
- Millennium Group Management LLC Owns 10% to 25% of Millennium Management LLC, since 07/2017 (Form ADV)
- Mlm Trust B LLC Owns 25% to 50% of Millennium Management LLC, since 04/2014 (Form ADV)
- Israel Alexander Englander Owns 10% to 25% of Millennium Management LLC, since 06/1989 (Form ADV)
- Petershill Millennium B Gp Aggregator LP Owns 5% to 10% of Millennium Management LLC, since 10/2025 (Form ADV)
- Petershill Millennium Gp Aggregator LP Owns 5% to 10% of Millennium Management LLC, since 10/2025 (Form ADV)
- George Rohr Owns control (general partner, trustee or manager) of Millennium Group Management Trust, since 07/2017 (Form ADV)
- Joshua Lionel Nash Owns control (general partner, trustee or manager) of Millennium Group Management Trust, since 07/2017 (Form ADV)
- MILLENNIUM MANAGEMENT LLC DE
- 10X Genomics Stake · Pleasanton, California, United States
- 2seventy bio, Inc. Stake · Cambridge, Massachusetts
- AbioMed Stake · Danvers, Massachusetts, United States
- Aclaris Therapeutics, Inc. Stake · Wayne, Pennsylvania, United States
- Adicet Bio, Inc. Stake · Boston, Massachusetts
- ADMA Biologics (United States) Stake · Ramsey
- Aerojet Rocketdyne Holdings Stake · Rancho Cordova, California, United States
- Aimco Stake · Denver, Colorado, United States
- Akili, Inc. Stake · Boston, Massachusetts
- AleAnna, Inc. Stake · Dallas, Texas
- Allakos Inc. Stake · San Carlos, California, United States
- Altimmune, Inc. Stake · Gaithersburg, Maryland, United States
- ALX ONCOLOGY HOLDINGS INC Stake · South San Francisco, California
- AMC Global Media Stake · New York, New York, United States
- AMC Theatres Stake · Leawood, Kansas, United States
- Ameresco Stake · Framingham, Massachusetts, United States
- American Healthcare REIT, Inc. Stake · Baltimore, Maryland, United States
- American National Group Inc. Stake · Houston, Texas
- AMERICAN VANGUARD CORP Stake · Newport Beach, California
- AMERISAFE INC Stake · Deridder, Louisiana, United States
- Amylyx Pharmaceuticals Stake · Cambridge
- ANAPTYSBIO, INC Stake · San Diego, California, United States
- ANGIODYNAMICS INC Stake · Wilmington, Delaware, United States
- ANI PHARMACEUTICALS INC Stake · Wilmington, Delaware, United States
- Anthemis Digital Acquisitions I Corp Stake · New York, New York
- and 280 more
Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (305 companies); owners and owned firms from Form ADV, the registration investment advisers file with the SEC. Each entity in the chart links to its source.
Investment adviser
MILLENNIUM MANAGEMENT LLC is registered with the SEC as an investment adviser. This is what it reports on Form ADV, the registration every adviser files and keeps current.
- Assets it manages$720.8B2 35 accounts, all with discretion
- Employees6,670 3,055 in investment advice or research
- ClientsPooled investment vehicles (other than investment companies and: 27 ($709.3B)
- How it is paidA percentage of assets under its management; Performance-based fees; Other: REIMBURSEMENT OF EXPENSES
- What it doesPortfolio management for pooled investment vehicles (other than investment companies); Portfolio management for businesses (other than small businesses) or institutional clients (other than registered investment companies and other pooled investment vehicles)
- Holds client assetsYes: cash and securities
- RegistrationSEC 801-73884, CRD 158117 IAPD record
Who owns it
Owners of 5% or more as the firm lists them (Schedule A), and the owners of those owners up the chain (Schedule B).
- MLM TRUST B LLCowns 25% to 50%, since 04/2014
- Israel Alexander Englanderowns 10% to 25%, since 06/1989
- MILLENNIUM GROUP MANAGEMENT LLCowns 10% to 25%, since 07/2017
- PETERSHILL MILLENNIUM B GP AGGREGATOR LPowns 5% to 10%, since 10/2025
- PETERSHILL MILLENNIUM GP AGGREGATOR LPowns 5% to 10%, since 10/2025
- Charles Tappan Dowlingowns general partner, trustee or manager of MLM TRUST G, since 05/2025
- Charles Tappan Dowlingowns general partner, trustee or manager of MLM TRUST G LLC, since 05/2025
- Israel Alexander Englanderowns general partner, trustee or manager of MILLENNIUM GROUP MANAGEMENT TRUST, since 07/2017
- Gregory James Flemingowns general partner, trustee or manager of MILLENNIUM GROUP MANAGEMENT TRUST, since 06/2019
- ICAPITAL HF GP, LLCowns general partner, trustee or manager of PETERSHILL MILLENNIUM INVESTORS (ICAPITAL) PARTNER OFFSHORE, L.P., since 10/2025
- ICAPITAL HF GP, LLCowns general partner, trustee or manager of PETERSHILL MILLENNIUM INVESTORS (ICAPITAL), L.P. PARTNER, since 10/2025
- MAPLESFS LIMITEDowns general partner, trustee or manager of IM CHARITABLE SHARE TRUST, since 03/2021
- MILLENNIUM GROUP MANAGEMENTowns general partner, trustee or manager of MILLENNIUM GROUP, since 07/2017
- Joshua Lionel Nashowns general partner, trustee or manager of MILLENNIUM GROUP MANAGEMENT TRUST, since 07/2017
- George Rohrowns general partner, trustee or manager of MILLENNIUM GROUP MANAGEMENT TRUST, since 07/2017
- George Rohrowns general partner, trustee or manager of MLM TRUST B, since 10/2018
- George Rohrowns general partner, trustee or manager of MLM TRUST B LLC, since 10/2018
- Joseph Chaim Shenkerowns general partner, trustee or manager of MILLENNIUM GROUP MANAGEMENT TRUST, since 05/2025
- IM CHARITABLE SHARE TRUSTowns 75% or more of PETERSHILL MILLENNIUM ADVISORS LLC MEMBER, since 09/2025
- MLM TRUST Bowns 75% or more of MLM TRUST B LLC, since 04/2014
- MLM TRUST Gowns 75% or more of MLM TRUST G LLC, since 05/2025
- MLM TRUST G LLCowns 50% to 75% of MILLENNIUM GROUP MANAGEMENT LLC, since 05/2025
- MOUNT EVEREST S.A. SICAV-RAIFowns 50% to 75% of PETERSHILL MILLENNIUM INVESTORS (ICAPITAL) PARTNER OFFSHORE, L.P., since 10/2025
- PETERSHILL MILLENNIUMowns 50% to 75% of PETERSHILL MILLENNIUM GP, since 08/2025
- PETERSHILL MILLENNIUMowns 25% to 50% of PETERSHILL MILLENNIUM, since 10/2025
- PETERSHILL MILLENNIUM L.P.owns 25% to 50% of PETERSHILL MILLENNIUM, since 10/2025
Disciplinary record
The firm answered yes to 5 of the disciplinary questions on Form ADV (Item 11). A yes can concern the firm itself or an affiliate.
- The SEC or the CFTC has found the firm or an advisory affiliate to have been involved in a violation of SEC or CFTC regulations or statutes.
- The SEC or the CFTC has entered an order against the firm or an advisory affiliate in connection with investment-related activity.
- The SEC or the CFTC has imposed a civil money penalty on the firm or an advisory affiliate, or ordered the firm or an advisory affiliate to cease and desist from any activity.
- Any other federal regulatory agency, any state regulatory agency, or any foreign financial regulatory authority has found the firm or an advisory affiliate to have been involved in a violation of investment-related regulations or statutes.
- Any self-regulatory organization or commodities exchange has found the firm or an advisory affiliate to have been involved in a violation of its rules (other than a violation designated as a "minor rule violation" under a plan approved by the SEC).
Each event as the firm describes it on its Disclosure Reporting Pages:
SWEDISH FINANCIAL SUPERVISORY AUTHORITY ("SFSA") · Jan 29, 2016 · fine $41,450 · final
Allegations: THE FIRM SELF-REPORTED TO THE SFSA THE NET SHORT POSITION IN THE SHARES OF A SINGLE SWEDISH ISSUER. THE FILING WAS MADE INADVERTENTLY LATER THAN THE NEXT DAY FILING DEADLINE.
Sanction: Other
How it ended: Decision
Detail: THE SFSA DECIDED TO REQUIRE THE FIRM TO PAY A SPECIAL FEE OF 400,000 SWEDISH KRONA (APPROXIMATELY $41,450 USD).
Summary: APPEAL WAS DENIED.
Resolved: Nov 6, 2019
SECURITIES AND EXCHANGE COMMISSION · Oct 31, 2017 · fine $300,000 · final
Allegations: MILLENNIUM MANAGEMENT LLC (THE "MILLENNIUM RESPONDENT") WAS ALLEGED TO HAVE VIOLATED RULE 105 OF REGULATION M OF THE SECURITIES EXCHANGE ACT OF 1934 ("RULE 105").
Sanction: Cease and Desist
How it ended: Settled
Detail: CIVIL MONEY PENALTY: $300,000 DISGORGEMENT AND PREJUDGMENT INTEREST: $338,709.11 (FOR A TOTAL OF $638,709.11, WHICH WAS PAID ON NOVEMBER 6, 2017.)
Summary: ON OCTOBER 31, 2017, THE MILLENNIUM RESPONDENT CONSENTED, WITHOUT ADMITTING OR DENYING THE FINDINGS THEREIN, TO THE ENTRY OF AN ORDER ISSUED BY THE SEC FINDING THAT ON FOUR OCCASIONS IN 2012 IT VIOLATED RULE 105 OF REGULATION M OF THE US SECURITIES EXCHANGE ACT OF 1934. (SEE SEC RELEASE NO. 34-81989.) IN SETTLEMENT OF THIS MATTER, THE MILLENNIUM RESPONDENT AGREED TO PAY A CIVIL MONEY PENALTY OF $300,000, AS WELL AS DISGORGEMENT AND PREJUDGMENT INTEREST OF $338,709.11 AND TO CEASE AND DESIST FROM COMMITTING OR CAUSING ANY VIOLATIONS AND ANY FUTURE VIOLATIONS OF RULE 105 OF REGULATION M OF THE EXCHANGE ACT.
Resolved: Oct 31, 2017
SWEDISH FINANCIAL SUPERVISORY AUTHORITY ("SFSA") · Jan 25, 2018 · fine $518 · final
Allegations: THE FIRM SELF-REPORTED TO THE SFSA THE NET SHORT POSITION IN SHARES OF A SINGLE SWEDISH ISSUER. THE FILING WAS INADVERTENTLY LATER THAN THE NEXT FILING DAY.
Sanction: Other
How it ended: Decision
Detail: THE SFSA DECIDED TO REQUIRE THE FIRM TO PAY A SPECIAL FEE OF 5,000 SWEDISH KRONA (APPROXIMATELY $518 USD)
Summary: APPEAL WAS DENIED.
Resolved: Nov 6, 2019
SWEDISH FINANCIAL SUPERVISORY AUTHORITY ("SFSA") · Nov 6, 2019 · fine $20,000 · final
Allegations: IN THE MATTER 16932-18: THE FIRM TIMELY FILED WITH THE SFSA THE NET SHORT POSITION IN THE SHARES OF A SINGLE SWEDISH ISSUER. HOWEVER, THE FILING CONTAINED A TYPOGRAPHICAL ERROR, WAS LATER CORRECTED BUT NONETHELESS CONSIDERED BY THE SFSA TO HAVE BEEN FILED LATER THAN THE NEXT DAY FILING DEADLINE. IN THE MATTER 16937-18: THE FIRM FILED THE NET SHORT POSITION IN THE SHARES OF A SINGLE SWEDISH ISSUER INADVERTENTLY LATER THAN THE NEXT DAY FILING DEADLINE. THE FIRM SELF-REPORTED THE LATE FILING TO THE SFSA.
Sanction: Other
How it ended: Decision
Detail: THE SFSA DECIDED TO REQUIRE THE FIRM TO PAY A SPECIAL FEE OF 113,700 SWEDISH KRONA (APPROXIMATELY $13,800 USD) (16937-18) AND 51,200 SWEDISH KRONER (APPROXIMATELY $6,200 USD) (16932-18), COLLECTIVELY $20,000.
Summary: APPEAL WAS DENIED.
Resolved: Nov 11, 2020
FINANSTILSYNET - THE FINANCIAL SUPERVISORY AUTHORITY OF NORWAY · Oct 29, 2021 · fine $4,556 · final
Allegations: CERTAIN NET SHORT POSITION FILINGS OF NORWEGIAN ISSUERS WERE INADVERTENTLY MADE SHORTLY AFTER THE NEXT DAY FILING DEADLINE.
Sanction: Other
How it ended: Decision
Detail: THE FINANCIAL SUPERVISORY AUTHORITY OF NORWAY DECIDED TO IMPOSE A VIOLATION PENALTY IN THE AMOUNT OF NOK 40,000 ($4556 USD)
Summary: THE FINANCIAL SUPERVISORY AUTHORITY OF NORWAY DECIDED TO IMPOSE A VIOLATION PENALTY IN THE AMOUNT OF NOK 40,000 ($4556 USD)
Resolved: Jan 6, 2022
CME GROUP INC. · Nov 21, 2022 · fine $90,000 · final
Allegations: THE CME ALLEGED THAT REGISTRANT VIOLATED NYMEX RULES 432.Q AND 432.W (ACT DETRIMENTAL TO EXCHANGE/SUPERVISION) WITH RESPECT TO SENDING TWO SEPARATE FUTURES ORDERS TO A THIRD PARTY FCM'S TRADING EXECUTION ALGORITHM (WHICH THEN PLACED MULTIPLE ORDERS FOR THE REGISTRANT ON THE FUTURES EXCHANGE), WHICH, IN ONE CASE, RESULTED IN A TRADING HALT.
Sanction: Civil and Administrative Penalt(ies) /Fine(s)
How it ended: Settled
Detail: A FINE OF $90,000 WAS PAID BY REGISTRANT ON DECEMBER 22, 2022.
Summary: WITHOUT ADMITTING OR DENYING THE VIOLATIONS OR FACTUAL FINDINGS, ON DECEMBER 15, 2022 REGISTRANT AGREED TO PAY A FINE OF $90,000.
Resolved: Dec 15, 2022
CBOE EXCHANGE, INC. · Dec 27, 2024 · fine $650,000 · final about Schadewald, Douglas, Lee
Allegations: PRIOR TO DOUGLAS SCHADEWALD'S EMPLOYMENT WITH REGISTRANT, AND DURING THE TIME THAT HE WAS AFFILIATED WITH JANE STREET OPTIONS, LLC ("JSOP"), SCHADEWALD AND JSOP WERE ALLEGED TO HAVE VIOLATED CBOE RULE 8.1 AND 8.16 IN MAY 2021. NEITHER JSOP NOR SCHADEWALD ADMIT OR DENY THAT VIOLATIONS OF EXCHANGE RULES HAVE BEEN COMMITTED.
Sanction: Censure
How it ended: Consent
Detail: CBOE IMPOSED A JOINT AND SEVERAL FINE IN THE AMOUNT OF $650,000 THAT WAS PAID IN FULL BY JANE STREET OPTIONS, LLC. CBOE DID NOT IMPOSE ANY SUSPENSION, BAR, RE-QUALIFICATION CONDITION, EXAMINATION OR RETRAINING REQUIREMENT.
Summary: LETTER OF CONSENT, EFFECTIVE DECEMBER 27, 2024, INCLUDES A WAIVER OF THE RIGHT TO APPEAL. No Information Filed
Resolved: Dec 27, 2024
In its own words: the client brochure
Form ADV Part 2A, the plain-English document an adviser must give its clients, quoted as filed 8/25/2026.3 It covers the firm’s services, fees, investment strategies and their risks, and its conflicts of interest.
Item 4: Advisory business Services
Millennium Management LLC (“Millennium Management”), a Delaware limited liability company, and its predecessors have been in business since 1989. Millennium Management and its relying advisers (identified in Item 10 of this Brochure, as well as on Schedule R of Millennium Management’s Form ADV Part 1) (each a “Relying Adviser” and together the “Relying Advisers”) provide discretionary investment advisory services to certain private funds in accordance with their investment objectives and strategies as broadly described in Item 8 of this Brochure. In addition, certain of our Relying Advisers entered into separately managed account agreements to provide discretionary investment advisory services to certain investors, which services are tailored based on the relevant investor’s individual investment objectives, guidelines and/or limitations on the types of securities and other instruments in which the given portfolio may invest. Unless specifically noted otherwise, the responses to this Form ADV Part 2A combine information about Millennium Management and its Relying Advisers. Millennium Management and its affiliated entities are collectively referred to throughout this Brochure as “Millennium.” Millennium Management and its Relying Advisers are collectively referred to throughout this Brochure as the “Firm” or by use of the first person plural pronoun. Each of the private funds we manage is generally referred to throughout this Brochure as a “Fund” and are collectively referred to throughout this Brochure as the “Funds.” Certain Funds, directly or indirectly, invest all or substantially all of their assets in other Funds in a master-feeder structure, with the feeder funds in such master-feeder structure referred to throughout this Brochure as “Feeder Funds”. Each separately managed account we manage is generally referred to throughout this Brochure as a “Separate Account.” The Funds and Separate Accounts (and portfolios of Separate Accounts, as the case may be) are referred to throughout this Brochure as “Clients.” The principal of Millennium Management is Israel Englander. Mr. Englander and certain companies and trusts for his benefit and the benefit of his family (including MLM Trust B) directly or indirectly own a majority of the economic interests of Millennium Management. As of December 31, 2025, we managed approximately $109,719,865,000 in net assets for the Clients (including the Millennium Partners Funds and the WMA Funds (each as defined herein) and the Separate Accounts, but excluding, for the avoidance of doubt, uncalled capital of the Millennium Partners Funds). All of these assets are managed on a discretionary basis.
-4-
Item 5: Fees and compensation Fees
Funds The fees, expenses and/or allocations associated with an investment in a Fund vary, depending on the specific Fund, and are detailed in the Fund’s offering document. Any applicable fees, expenses and/or allocations are deducted from a Fund investor’s assets as described in such Fund’s offering document. Performance-based allocations or fees are generally allocated or paid, respectively, annually and upon an investor’s withdrawal or redemption from the applicable Fund. In the case of one Millennium Partners Fund, asset-based fees are paid quarterly in advance and are generally subject to proration for (i) a subscription that does not fall on the first day of a quarter or (ii) a withdrawal or redemption that does not fall on the last day of a quarter. Millennium Partners, L.P. (“Millennium Partners”) and its Feeder Funds (together with Millennium Partners as the context may require, the “Millennium Partners Funds”) The Millennium Partners Funds generally bear, directly or indirectly, all expenses incurred in connection with the operation of the Millennium Partners Funds, without limitation (which are therefore borne by the investors in the Millennium Partners Funds), other than as described in Item 11 under “Portfolio Manager Investment in Own Strategies.” We generally refer to this as an “expense pass-through.” Each Millennium Partners Fund also pays us a performance-based allocation and/or an asset-based fee, and is generally responsible for:
a generally pro rata portion of all of the fees and expenses that such Millennium Partners Fund and its affiliates incur (which include, among other things, the salaries, fringe benefits, bonuses, fees and performance-based compensation (collectively, “compensation”) and expenses paid or reimbursed to Portfolio Managers (as defined in Item 8 of this Brochure), other employees, consultants, subcontractors and agents, fees paid to persons or entities who assist in identifying and recruiting Portfolio Managers, expenses related to computers and other equipment and expenses related to maintaining offices, including leases and fixtures); and
all fees and expenses incurred in connection with any transactions, engagements, and other agreements that such Millennium Partners Fund enters into on its own behalf, including, among other things, costs and expenses of its administrator, expenses incurred in connection with the private placement of interests (other than placement fees), and, with respect to non-U.S. Millennium Partners Funds, directors’ fees and expenses.
Millennium Partners Funds in the aggregate bear all of the compensation paid to the Portfolio Managers (including Portfolio Managers that are Relying Advisers) and other employees of, and consultants to, the Firm and its affiliates. The compensation expenses also include management or “base” fees that are charged by certain Portfolio Managers or third-party funds. In addition, certain personnel who assist in overseeing groups of Portfolio Managers (e.g., the head of a particular strategy) receive compensation based on the overall performance of such Portfolio Managers. This compensation of Portfolio Managers and such personnel responsible for overseeing Portfolio Managers (as well as other Millennium employees) is separate from and in addition to the performance- and/or asset-based compensation we receive from the Millennium Partners Funds, which compensates us for services provided by our principal. Such expense is deducted prior to calculation of the performance- and/or asset-based compensation we receive from the Millennium Partners Funds. Compensation of a Portfolio Manager is generally determined as a percentage of profits earned by such Portfolio Manager during the preceding calendar year, with profits measured on an accrual (i.e., markto-market) basis and without taking into account the performance of other Portfolio Managers or of the Millennium Partners Funds generally. If a Portfolio Manager suffers net losses during the year, generally the losses are carried forward and past losses must be made up before performance-based compensation becomes payable in subsequent years. Portfolio Managers also receive a salary, which is generally treated as an advance against their performance-based compensation if there are profits (although, for certain Portfolio Managers, salary is instead treated as an expense of their respective accounts). There is generally no “carryback” or “clawback” of losses to permit recouping of performance-based compensation from prior years. Portfolio Managers with positive performance will receive performance-based compensation even if -5-
the Millennium Partners Funds’ overall returns are negative. We have agreed, and may in the future agree, to “guarantee” a level of compensation for a Portfolio Manager or other personnel for a particular year (or years) or to replace compensation that a Portfolio Manager or other personnel has forfeited in connection with the termination of prior employment. We have from time to time in the past negotiated, and may in the future negotiate, different compensation arrangements with Portfolio Managers and other personnel than those described above. In addition to the expenses listed above, the expenses of the Millennium Partners Funds, which are paid directly or indirectly by such Millennium Partners Funds, include all expenses directly or indirectly related to such Millennium Partners Funds’ investment activities, including, without limitation, brokerage commissions and interest expense; internal and external accounting expenses; audit and tax (including withholding tax) expenses; legal expenses; administrator, registrar and transfer agent fees and expenses; premiums for general partner liability insurance and risk-specific insurance and “key-man” life insurance on certain personnel; and other administrative and operating expenses. The capital to establish, capitalize and maintain the non-U.S. management companies has been provided to Millennium International Management by Millennium Partners through inter-company arrangements, and as such the expenses attributable to these arrangements are paid by the Feeder Funds. All determinations as to whether particular expenses are payable by the Feeder Funds are made by the Firm in the reasonable exercise of its discretion. We may from time to time in the future advise additional funds or accounts with expense pass-through arrangements similar to the foregoing. WMQS Global Equity Active Extension Master Fund LP (the “WMQS GEAE Master”) and its Feeder Funds (together with the WMQS GEAE Master as the context may require, the “WMQS GEAE Funds”), WMA Systematic Equity Alpha Long/Short Master Fund LP (the “WMA SEALS Master”) and its Feeder Funds (together with the WMA SEALS Master, the “WMA SEALS Funds”), WMA AE Institutional Fund I LP (“WMA AE Institutional”), WMA Global Large Cap Enhanced Equity Master Fund LP (the “WMA GLCEE Master”) and its Feeder Funds (together with the WMA GLCEE Master as the context may require, the “WMA GLCEE Funds”), WMA US Active Extension Master Fund (“WMA USAE Master”) and its Feeder Funds (together with the WMA USAE Master as the context may require, the “WMA USAE Funds”), WMA International ex-US ex-HK Active Extension Master Fund LP (the “WMA IEAE Master”) and its Feeder Funds (together with the WMA IEAE Master as the context may require, the “WMA IEAE Funds”), WMA US Large Cap Enhanced Equity Master Fund LP (the “WMA USLCEE Master”) and its Feeder Funds (together with the WMA USLCEE Master as the context may require, the “WMA USLCEE Funds”), and WMA Systematic Alpha Broad US Equity Return Master Fund LP (the “WMA SABER Master”) and its Feeder Fund (together with the WMA SABER Master as the context may require, the “WMA SABER Funds”) and WMA AE Institutional ex-HK Fund I LP (“WMA Global ex-HK Fund”). The WMQS GEAE Funds, the WMA SEALS Funds, WMA AE Institutional, the WMA GLCEE Funds, the WMA USAE Funds, the WMA IEAE Funds, the WMA USLCEE Funds, the WMA SABER Funds, and the WMA Global ex-HK Fund are collectively referred to herein as the “WMA Funds”. The WMA Funds are subject to the fee and allocation arrangements, and bear such expenses, as are set forth in the terms of such WMA Funds. The WMA Funds pay us flat asset-based fees and/or performance-based fees. The WMA Funds are generally responsible for the WMA Funds’ direct expenses (and generally a pro rata share of the expenses of the applicable master fund) as set forth in the WMA Funds offering documents. Examples of the types of expenses borne by the WMA Funds include, but are not limited to, investment expenses, whether or not such investments are consummated (such as brokerage commissions, expenses relating to short sales, clearing and settlement charges, custodial fees, bank service fees and interest expenses); certain market data costs; third-party professional fees (including, without limitation, expenses of consultants, attorneys, accountants and other experts) relating to investments; directors’ fees and expenses; third-party administrative fees and expenses (including fees and expenses of the administrator); third-party legal expenses (including the updating of such WMA Fund’s offering documents, processing transfer requests, negotiations with prospective investors and extraordinary legal expenses, such as those related to litigation or regulatory investigations or proceedings); third-party accounting and valuation expenses (including, without limitation, the cost of accounting software packages); third-party audit and tax preparation expenses; fees, expenses (including, without limitation, expenses related to the organization and conduct of investor meetings (including, without limitation, travel, lodging and meal expenses)), if any; costs of printing and mailing reports and notices; entity-level taxes (including, without limitation, investor-related taxes); third-party expenses -6-
related to preparing and making regulatory and compliance filings associated with such WMA Fund and its investment activities, such as filing fees and costs of software and systems relating to such filings; organizational expenses; expenses incurred in connection with the offering and sale of the interests and other similar expenses related to such WMA Fund (excluding fees payable to any placement agent); indemnification expenses; extraordinary expenses; and the cost of certain Bloomberg terminals in support of investment activities, operations and middle office. General We may from time to time in the future advise additional Funds or Separate Accounts with expense arrangements similar to or different from the foregoing. Such Funds or Separate Accounts may bear additional expenses as permitted under the terms of such Fund’s or Separate Account’s governing documents. Certain expenses are shared across different Funds or across the Funds and other businesses of the Firm and allocated among the Funds and the Firm in accordance with our expense allocation methodologies. Our expense allocation methodologies and certain conflicts of interest that may be raised by them are discussed further in Item 11 of this Brochure. The Funds incur brokerage and other transaction costs, as discussed further in Item 12 of this Brochure. Separate Accounts Certain WMA (as defined herein) Relying Advisers have entered into separately managed account agreements to advise Separate Accounts. Fees and expenses associated with each Separate Account (including the form, method of calculation and timing of our compensation) were negotiated before the applicable investment advisory relationship commenced and are set forth in detail in the relevant investment management agreement entered into with the holder of such account. Fees will generally be charged quarterly or annually in arrears and calculated based on the average of the market value of the portfolio on the last business day of the relevant period. The holder of each Separate Account has elected to be billed directly for fees. The holder of each Separate Account is responsible for its own costs and expenses, including custodial fees and brokerage and transactions costs (as discussed further in Item 12 of this Brochure). We may in the future enter into agreements to manage additional separate accounts for Separate Account Clients, and such agreements may provide for different compensation arrangements, including with respect to the form, method of calculation and timing of our compensation, as well as any agreement as to the bearing of expenses. In all cases, the compensation arrangement with a Separate Account Client will be negotiated and agreed upon in writing before the commencement of the advisory relationship for the relevant Separate Account.
-7-
Item 8: Methods of analysis, investment strategies and risk of loss Investment strategies and risks
We manage the capital of each Fund in accordance with its investment objectives, which are broadly set forth in the applicable Fund’s offering document. The investment objective and parameters for a Separate Account are set forth in the investment management agreement with the applicable Separate Account Client. Millennium Partners Funds For the Millennium Partners Funds, we follow an investment strategy that is opportunistic with respect to investments and strategies and that is broadly diversified and global in scope. We do so by selecting, monitoring and evaluating Portfolio Managers and allocating and reallocating the Millennium Partners Funds’ invested capital among them. For the Millennium Partners Funds, we also make direct (i.e., not through Portfolio Managers) investments of the Millennium Partners Funds’ capital, either as a profit-seeking investment (e.g., direct trading activities) or as hedges, or “contra” trades that seek to establish a reduction in certain exposures. Our direct trading activities with respect to the Millennium Partners Funds have included, and may in the future include, increasing (potentially materially) the Millennium Partners Funds’ exposure to certain strategies or positions or to netted positions held by a number of Portfolio Managers. However, there is no obligation for us to engage in such activities. Additionally, there is no guarantee that direct trading activities will be profitable, and, with respect to increasing the Millennium Partners Funds’ exposure to certain strategies or positions, such activities may exacerbate any losses associated with such strategies or positions. Consistent with this approach (and unlike many investment partnerships that as a matter of investment policy require that no more than a fixed percentage of their assets be invested in any one industry or group of industries), we do not establish fixed guidelines regarding diversification of investments to be followed by the Millennium Partners Funds. At any given time, the Millennium Partners Funds’ assets could be concentrated in securities or asset classes that the Portfolio Managers (subject to the oversight of our Risk Management group) believe offer an optimal opportunity for appreciation. However, by virtue of our structure, in which assets are allocated among a number of Portfolio Managers utilizing different strategies and investment approaches, as well as our general risk management principles, which discourage concentrations and apply Firm-wide oversight, the Millennium Partners Fund’s assets will usually be deployed among a diversified set of strategies. The investment strategies that the Millennium Partners Funds employ include, among other things, most or all of the following core strategy classifications, each of which is comprised of a number of component strategies: fundamental equity; quantitative strategies; equity arbitrage; fixed-income; and commodities. The Millennium Partners Funds may, and typically do, also invest in certain other strategies, including, among others, closed-end fund/asset arbitrage and distressed investing, and may reclassify, and have reclassified, strategies or components thereof from time to time. However, as noted above, the Millennium Partners Funds may concentrate investments in a select few strategies while not employing others and may employ additional investment strategies or suspend any such strategies, as determined by us in our discretion, at any time without notice. There are no substantive limits on the investment strategies that may be pursued by the Millennium Partners Funds. As used in this Brochure, the term “Portfolio Manager” refers to a group of one or more (and often many more) investment professionals operating as a single team to manage all or a portion of a particular Fund’s assets, under the supervision of one or more individuals referred to as a senior portfolio manager or portfolio manager. In some instances the day-to-day responsibility for the oversight of a portion of the assets is allocated to a Portfolio Manager’s team, who may also be “portfolio managers.” Although most of the Firm’s Portfolio Managers are actively involved in the day-to-day investment decision-making process with respect to their respective strategies, we may, and do, allocate capital to Portfolio Managers who manage larger teams and whose primary function is to oversee and manage other investment personnel that are responsible for making investment decisions within a particular strategy or strategies. Most Portfolio Managers are employed by Millennium, while certain others are third-party investment management firms whose employees are not employed by Millennium, including in certain cases Relying Advisers. Certain Portfolio Managers employed by Millennium form limited liability companies or other entities in connection with the performance of their services to Millennium. Portfolio Managers operate their respective trading groups and are primarily responsible for their groups’ trading, personnel, and similar decisions, subject to our risk management and, in the case of Portfolio Managers that are Millennium employees or that are Relying Advisers, to Millennium’s supervision and control. Portfolio Managers whose personnel are not employees of Millennium are responsible for the hiring of personnel and certain other aspects of their business, although Millennium generally retains ultimate control over the Millennium accounts managed by such Portfolio Managers. Certain of such Portfolio Managers also manage capital for one or more other clients. Certain Portfolio Managers who were previously employed by
- 10 -
Millennium or who managed assets of the Funds exclusively have formed their own investment management firms and provide services to Millennium as well as other clients, and others may do so in the future. In some cases, Millennium Partners Funds’ capital is invested in investment funds or similar structures managed by third-party Portfolio Managers. A third-party Portfolio Manager (or another third party) will in certain instances retain control of the vehicle (and certain accounts held in the name of such vehicle) in which Millennium Partners invests. Unlike with respect to the managed accounts typically established by Millennium Partners when retaining third-party Portfolio Managers, when investing in a separate fund or vehicle not controlled by the Firm, funds are sent to, and held in the name of, such fund or vehicle (and not held by and in the name of Millennium Partners). In addition, in such structures, Millennium Partners may have less frequent liquidity, less transparency into trading activity and other similar limitations relative to managed account relationships. Such third-party Portfolio Managers may be subject to their own supervisory and compliance requirements, separate from Millennium’s, and may make judgments in connection therewith. All of the foregoing may adversely impact Millennium Partners. A Fund or Millennium will from time to time also take an equity stake in the third-party Portfolio Manager’s management company or receive other economic rights with respect to the activities of third-party Portfolio Managers. A Fund has in the past entered into, and may in the future enter into, from time to time, joint venture arrangements (including with Portfolio Managers), co-invest with third parties, provide seed capital to managers, enter into arrangements to receive, directly or through Millennium, a portion of the profits or revenue generated by third-party Portfolio Managers, structure compensation arrangements with Portfolio Managers in the form of an incentive allocation or profits interest in a fund vehicle in which Millennium Partners invests, and/or enter into relationships that encompass elements of more than one of these categories, as well as new structures that Millennium determines are appropriate for Millennium Partners. In addition, Millennium Partners (or Millennium on its behalf) has in the past acquired and may in the future acquire all or a portion of the assets (including goodwill) of an external asset manager, in connection with retaining the services of a Portfolio Manager, and it may in the future determine to acquire all or a portion of the equity of a Portfolio Manager. WMA Funds The WMA Funds are ultimately managed by a single Portfolio Manager, WorldQuant (as defined below), and have more specific strategies, investment types, markets or countries in which they invest than the Millennium Partners Funds and/or are subject to target parameters to which the Millennium Partners Funds are not subject. WorldQuant utilizes systematic, model-based strategies for data sourcing and processing, “alpha” research, strategy development and portfolio management. Separate Accounts Each Separate Account is managed by a Relying Adviser and utilizes a strategy for which WorldQuant’s systematic, model-based strategies for data sourcing and processing, “alpha” research, strategy development and portfolio management are utilized. Risk Factors The following are certain risk factors describing risks related to the trading strategies and instruments we may implement for Clients, and the investment techniques we may utilize. This list is not exhaustive and not all of the investment strategies, instruments, and associated risks discussed herein are relevant to all Clients. There can be no assurance that the objectives associated with any strategies described above will be met. At any time, Millennium may add, remove, modify, overweight or underweight any of the strategies or factors it employs. Prospective Fund investors should carefully review the offering documents for a Fund for a more detailed discussion of the Fund’s strategies and related risks and for discussion of the conflicts of interest of the adviser and its related persons in connection with the Fund. In the event of any differences, the disclosure in the applicable offering documents will control. Certain Market and Investment Risks Investment and Trading Risks in General. Inherent in any investment in securities is the risk of losing the invested capital. We believe that a Client’s investment program and the Portfolio Managers’ research techniques moderate this risk through a careful selection of securities and investment opportunities, as well as through the application of our - 11 -
Item 7: Types of clients
We manage private funds, and certain Relying Advisers have entered into separately managed account agreements to provide discretionary investment advisory services to certain institutional investors. In the future, we may provide investment advice to other clients, including other funds and separately managed accounts. We require Separate Account Clients to enter into a written investment management agreement. Minimum account sizes will vary and we may waive any account minimum.
-9-
Item 6: Performance-based fees and side-by-side management Conflicts of interest
As described in Item 5 of this Brochure, we may charge both asset-based fees based on the value of Client assets under management and/or performance-based fees (i.e., fees based on a share of capital gains on or capital appreciation of assets). Performance-based allocations or fees may, under some circumstances, create an incentive for Portfolio Managers to make investments that are riskier or more speculative than would be the case if the compensation were not performance-based, particularly in any period after losses have been suffered, as losses from prior periods must generally be recovered before any performance-based allocation or fee is payable. These arrangements may also create an incentive for Portfolio Managers to disproportionately allocate time, services or functions to Clients with performance-based allocations or fees, or to allocate particular investment opportunities to such Clients. Further, Portfolio Managers, who are generally compensated based on their performance, may have similar incentives to engage in more speculative activities than would be the case if their compensation were not performance-based, particularly in any period after losses have been suffered. This compensation structure may be seen to create an incentive for a Portfolio Manager to accept significant risks, in excess of levels that a Client might find acceptable, in seeking to obtain profits. Nonetheless, we have found the compensation scheme generally effective over time in providing trading incentives that correspond appropriately to each Client’s goals. Additional conflicts regarding the management of multiple Clients with different fee and expense structures are described in Item 11 of this Brochure.
-8-
Item 10: Other financial industry activities and affiliations Conflicts of interest
Millennium Group Management Trust, a revocable trust (together with any successor or residuary trust or trusts, the “Trust”) established in July 2017, serves as the ultimate controller of Millennium, including as the managing member of Millennium Group Management LLC, which is in turn the managing member of Millennium Management and the general partner of Millennium International Management. Mr. Englander serves as trustee of the Trust along with a number of other trustees (referred to herein collectively as the “Trustee Advisory Board”) as disclosed in Millennium Management’s Form ADV Part 1, as amended from time to time, with Mr. Englander retaining exclusive control of the Trust until his death or during any period of incapacity (as determined in accordance with the Trust). Following Mr. Englander’s death or during any period of incapacity, the remaining members of the Trustee Advisory Board would assume control of the Trust to be exercised by majority vote. Under the terms of the Trust, in such a circumstance, the trustees generally would be authorized to appoint additional and successor trustees meeting certain eligibility criteria specified by the Trust. It is expected that in such a circumstance where Mr. Englander dies or becomes incapacitated and the remaining trustees assume control, the day-to-day affairs of Millennium would continue to be managed by its senior management team, subject to the oversight of the Trustee Advisory Board until such time as a decision about ultimate succession is made by the Trustee Advisory Board (if applicable). Millennium Management (and certain other Millennium affiliated entities) completed a transaction with certain investment funds that have been established by the Petershill XIG business unit of Goldman Sachs Asset Management, L.P. (together with its affiliates, “Goldman Sachs,” and such investment funds, the “GS Funds”), whereby the GS Funds acquired non-controlling, minority (less than 15%) equity interests in these Millennium entities (the “Transaction”). The Transaction closed October 31, 2025. Mr. Englander (together with his affiliates) remains the largest, majority equity owner of Millennium. Millennium Management’s Relying Advisers are listed below, together with any applicable foreign licenses or registrations: 1.
MCM Italy S.r.l., an Italian private limited liability company.
2.
MCP (Switzerland) GmbH, a company incorporated in Switzerland, which is licensed by the Swiss Financial Market Supervisory Authority.
3.
Millennium Capital (DIFC) Limited, a private company incorporated in the Dubai International Financial Centre and regulated by the Dubai Financial Services Authority as a Category 3C Firm.
4.
Millennium Capital Jersey Limited, a Jersey limited company, which is registered with the Jersey Financial Services Commission.
5.
Millennium Capital Management (Australia) Pty Ltd, an Australian proprietary company limited by shares, which is licensed by the Australian Securities and Investments Commission.
6.
Millennium Capital Management (Hong Kong) Limited, a Hong Kong limited company, which is licensed by the Hong Kong Securities and Futures Commission.
7.
Millennium Capital Management (Mauritius) Ltd., a Mauritius private company limited by shares, which is licensed by the Republic of Mauritius Financial Services Commission.
8.
Millennium Capital Management (Monaco) S.A.M., a Monaco limited liability Company, regulated by La Commission de Contrôle des Activités Financières.
9.
Millennium Capital Management (Singapore) Pte. Ltd., a Singapore private company limited by shares, which is licensed by the Monetary Authority of Singapore.
10.
Millennium Capital Management Asia Limited, including its Tokyo Branch, a Hong Kong limited company, whose Tokyo Branch is licensed by the Japanese Financial Services Authority.
- 41 -
11.
Millennium Capital Management EMEA Israel Ltd, an Israeli private company limited by shares.
12.
Millennium Capital Management France SAS, a French société par actions simplifiée, which is authorized as an alternative investment fund manager by the Autorité des Marchés Financiers.
13.
Millennium Capital Partners LLP, a UK limited liability partnership, which is authorized and regulated by the UK Financial Conduct Authority as an investment firm, and has a South Africa branch.
14.
Millennium Global Estate GP LLC (“Millennium Global Estate GP”), a Delaware limited liability company. Millennium Global Estate GP has appointed an investment committee (the “Investment Committee”), which has responsibility for considering and evaluating, on behalf of Millennium Global Estate GP, the suitability of the allocation of capital made by Millennium Global Estate LP (“Millennium Global Estate”) to various investment strategies in accordance with the terms of Millennium Global Estate’s governing documents without the direct involvement of any known holders of insurance policies that have allocated premiums to Millennium Global Estate (the “Millennium Policyholders”) on behalf of Millennium Global Estate GP. The Investment Committee consists of members affiliated with Millennium Global Estate GP or its affiliates and, by the terms of its charter, at least one member who is not employed by, is not controlled by, is not under common control with, and does not control any Millennium Policyholder or its affiliates (an “unaffiliated member”).
15.
Millennium International Management LP (“Millennium International Management”), a Delaware limited partnership.
16.
MPG Capital Canada ULC, a British Columbia unlimited liability company.
17.
MPG PR Management LLC, a Puerto Rico limited liability company.
18.
Blue Arrow Capital Management LLC, a Delaware limited liability company.
19.
Cannon Asset Management LLC, a Delaware limited liability company.
20.
Catapult Capital Management LLC, a Delaware limited liability company.
21.
Decade Capital Management LLC, a Delaware limited liability company.
22.
Green Arrow Capital Management LLC, a Delaware limited liability company.
23.
WMA AE Institutional ex-HK GP I LLC, a Delaware limited liability company.
24.
WMA AE Institutional GP I LLC, a Delaware limited liability company.
25.
WMA ex-US ex-HK Active Extension GP LLC, a Delaware limited liability company.
26.
WMA Global Equity Active Extension GP LLC (formerly, WMQS Global Equity Active Extension GP LLC), a Delaware limited liability company.
27.
WMA Global Large Cap Enhanced Equity GP LLC, a Delaware limited liability company.
28.
WMA Global Management LLC (formerly, WMQS Global Management LLC), a Delaware limited liability company.
29.
WMA Systematic Alpha Broad US Equity Return GP LLC, a Delaware limited liability company.
- 42 -
30.
WMA Systematic Equity Alpha Long/Short GP LLC, a Delaware limited liability company.
31.
WMA US Active Extension GP LLC, a Delaware limited liability company.
32.
WMA US Large Cap Enhanced Equity GP LLC, a Delaware limited liability company.
33.
WorldQuant (Singapore) Pte. Ltd., a Singapore private company limited by shares, which is licensed by the Monetary Authority of Singapore.
34.
WorldQuant Hungary, LLC, Hungary Branch, a Hungarian branch of WorldQuant Hungary, LLC, which is a Delaware limited liability company.
35.
WorldQuant Millennium Advisors LLC (formerly, WorldQuant Millennium Quantitative Strategies LLC), a Delaware limited liability company.
36.
WorldQuant Millennium Institutional Advisors JP LLC, a Delaware limited liability company.
37.
WorldQuant Millennium Institutional Advisors LLC (formerly, WMA US Equity 130/30 GP LLC), a Delaware limited liability company.
38.
WorldQuant Millennium Institutional Advisors US LLC, a Delaware limited liability company.
39.
WorldQuant, LLC (“WorldQuant”), a Delaware limited liability company.
40.
Alphaton Technologies LLC (“Alphaton”), a Delaware limited liability company, which provides discretionary investment advice solely to Millennium Partners. Alphaton is subject to Millennium Management’s supervision and control, which is established by contractually obligating Alphaton to comply with Millennium’s policies and procedures, including Millennium’s Code (as defined below).
41.
Azur IM LP (“Azur”), a Delaware limited partnership, which provides investment advice solely to Millennium Partners and has no other clients. Azur is subject to Millennium Management’s supervision and control, which is established by contractually obligating Azur to comply with Millennium’s policies and procedures, including Millennium’s Code.
42.
Echion Capital LP (“Echion”), a Delaware limited partnership, which provides investment advice solely to Millennium Partners and has no other clients. Echion is subject to Millennium Management’s supervision and control, which is established by contractually obligating Echion to comply with Millennium’s policies and procedures, including Millennium’s Code.
43.
Ensphere Research, LLC (“Ensphere”), a Delaware limited liability company, which provides investment advice solely to Millennium Partners and has no other clients. Ensphere is subject to Millennium Management’s supervision and control, which is established by contractually obligating Ensphere to comply with Millennium’s policies and procedures, including Millennium’s Code.
44.
Gray Birch Asset Management LP (“Gray Birch”), a Delaware limited partnership, which provides investment advice solely to Millennium Partners and has no other clients. Gray Birch is subject to Millennium Management’s supervision and control, which is established by contractually obligating Gray Birch to comply with Millennium’s policies and procedures, including Millennium’s Code.
45.
Tamridge Capital, LLC (“Tamridge”), a California limited liability company, which provides investment advice solely to Millennium Partners and has no other clients. Tamridge is subject to Millennium Management’s supervision and control, which is established by contractually obligating Tamridge to comply with Millennium’s policies and procedures, including Millennium’s Code.
- 43 -
46.
Teragon Capital LP (“Teragon”), a Delaware limited partnership, which provides investment advice solely to Millennium Partners and has no other clients. Teragon is subject to Millennium Management’s supervision and control, which is established by contractually obligating Teragon to comply with Millennium’s policies and procedures, including Millennium’s Code.
Millennium Management, Millennium International Management and Millennium Global Estate GP are registered as commodity pool operators and commodity trading advisors, and Millennium Capital Management (Singapore) Pte. Ltd., WorldQuant Millennium Advisors LLC and WMA Global Management LLC are registered with the CFTC as commodity pool operators, and certain of their respective management persons are registered with the CFTC as associated persons. MFI Funding LLC, an indirect wholly-owned subsidiary of Millennium Partners, L.P., is registered with the CFTC as a futures commission merchant. MPG Operations LLC, a wholly-owned subsidiary of Millennium International Management, is a payroll entity that employs most of Millennium’s U.S.-based personnel. Mr. Englander and the other principals of our Firm and our affiliates devote to Clients as much of their time as, in their respective judgments, is necessary or appropriate in connection with such Clients’ activities. Our Firm, principals and affiliates, from time to time have in the past and may in the future, however, conduct other businesses. The conflicts related to such businesses are described in Item 11 of this Brochure.
- 44 -
Item 11: Code of ethics, participation or interest in client transactions and personal trading Conflicts of interest
We have adopted a Code of Ethics (the “Code”) setting forth a standard of business conduct expected of all of our employees (including compliance with federal securities laws). Among other things, the Code (through its reference to other policies incorporating them) sets forth policies and procedures designed to prevent insider trading and market manipulation. The Code also contains policies and procedures addressing personal trading. Employees are required to certify their compliance with the Code quarterly. We will provide a copy of our Code to Clients and prospective Clients upon request. Changes of Control and Certain Related-Party Transactions. With respect to the Funds, we, on behalf of the investors, are authorized to select one or more persons not affiliated with us, including a Fund’s unaffiliated directors, to serve on a committee as may be established from time to time in the future, the purpose of which is to consider and, on behalf of each Fund and its investors, approve or disapprove, to the extent required by applicable law or deemed advisable by us, principal transactions, other related-party transactions and other transactions and matters involving potential conflicts of interest, including without limitation changes in control of us and our affiliates. Such committee may approve of such matters prior to or contemporaneous with, or ratify such transactions subsequent to, the consummation of such matters. The person(s) so selected may be exculpated and indemnified by the Funds (or their associated master funds) in the same manner and to the same extent as we are. Personal Trading. As our related persons have invested, and may in the future invest, in the same securities (including options, warrants, futures, etc.) as a Client invests in based on our and our related persons’ investment advice, potential conflicts of interest may arise. We have adopted policies and procedures relating to personal trading by all personnel— including personnel of our affiliates—which are administered by our Compliance Department. Among other things, our policies and procedures include a pre-approval requirement for personal transactions (with certain limited exceptions, including broad-based indices and mutual funds) of all personnel. These requirements may be and in certain cases, after consideration, have been waived by us. Portfolio Managers generally are not permitted to hold positions that are identical or similar to the positions held in the portfolios they manage for a Fund. Such a situation could provide an incentive for a Portfolio Manager to trade in a way that would be advantageous to him or her personally but that would not be expected to have a positive effect on (and could even be adverse to) a Client. Consideration of such matters is a factor in our decision as to whether permission will be granted for any particular transaction. In addition, members of our management are permitted to (with prior approval of Compliance or the CLEO Committee (as described below), as appropriate) trade for their own accounts. From time to time, these activities may come into conflict with our business; if such a conflict were to arise, such personnel would generally be required to subordinate the interests of any other parties (or their own interests) to a Client, and in any event would be required to disclose the conflicts. We will endeavor to resolve any such conflicts in a manner that is fair and reasonable. Additionally, the Firm or its principal or other members of management may (with prior approval of Compliance or the CLEO Committee, as appropriate) from time to time pursue business opportunities other than the management of the Clients taking an interest in such fund’s management company and/or having a role in the management of such fund. In certain situations, the opportunity may have been first presented or considered by the Firm for a Client or made available to the principal or other members of the Firm’s management directly or indirectly because of the reputation, activities or relationships of a Client or its affiliates. From time to time, these activities may come into conflict with the Firm’s business. Clients and Fund investors will have no right to participate in any such opportunities. We will address, under the supervision of the CLEO Committee or any successor body thereto, any conflicts of interest that arise from such a situation in a manner we believe to be fair and equitable under the circumstances. Managing Multiple Client Accounts and Other Activities. We manage multiple Clients and may in the future create, sponsor or provide investment management, administrative or other services to funds, accounts, clients or other investment structures that are separate from and unrelated to our existing Clients and engage in other activities unrelated to our existing Clients. Numerous potential conflicts exist for us in providing services to multiple Clients. The nature and extent of such conflicts depend in part on the specific activities undertaken by us and the relative fee and expense structure of our Clients. Such conflicts include the need to allocate shared expenses and investment opportunities and other resources, and the diversion of time and attention of management, as well as competition for investment and management talent. We will attempt to mitigate such conflicts, under the ultimate supervision of the CLEO Committee or any successor body thereto, by making allocations and other judgments on a basis that we believe - 45 -
to be fair and reasonable under the circumstances, although it may not be possible fully or even partially to mitigate each such conflict, and such conflicts will not necessarily be resolved in the favor of any particular Client or the investors in any Fund. Allocation of Investment Strategies and Investments to and Among the Clients; Conflicting Investment Opportunities. We manage certain Client portfolios with similar investment programs, and may in the future manage Client portfolios that have investment programs similar to our existing Clients or that invest similarly to another Client’s portfolio or certain of its strategies. We do not currently, but may in the future, combine purchase or sale orders for securities of multiple Clients. A conflict arises when allocating transaction prices and expenses where multiple entities purchase or sell the same or substantially similar investment positions. We and our personnel may have incentives to favor one Client over another, including as a result of the manner in which we and our personnel are compensated by or in connection with the management of such Client, or based on the relative sizes of the investments in such Client by us or our personnel. We may determine, in accordance with our investment allocation policies adopted by us, as updated from time to time, which would likely be without notice to Clients or Fund investors (the “Investment Allocation Policy and Procedures”), that a particular investment strategy, investment opportunity, or investment with a particular Portfolio Manager, is appropriate for one or more Clients, but not for all Clients, or that is appropriate to be allocated in greater proportion to one or more Clients, in which case that investment may not be allocated to, or may be allocated in different proportions relative to the capital of, a Client (or Clients). Similarly, we may elect to allocate a particular investment or opportunity to one or more Funds in the same master-feeder structure, but not to others (or to allocate a particular investment or opportunity on a non pro rata basis). In some instances, investment strategies or investment opportunities that might have been available to and suitable for a Client may instead be utilized for or placed with another Client or may be utilized or made by us, or vice versa, and there is (i) no requirement that any Client receive any preference or priority with respect to investment strategies or investment opportunities and (ii) no limitation on a Client receiving such preference or priority in accordance with the Investment Allocation Policies and Procedures. WorldQuant, a Relying Adviser, serves as a Portfolio Manager (or in a similar capacity) for multiple Clients that we manage, specifically as one of the Portfolio Managers of the Millennium Partners Funds and as the sole Portfolio Manager for the WMA Funds, and as a Portfolio Manager to Separate Accounts, which are managed by a joint venture between WorldQuant and Millennium (“WMA”). Investment strategies developed by WorldQuant are allocated among Clients based on their respective investment programs in accordance with the Investment Allocation Policy and Procedures. Specifically, we have established allocation criteria for WorldQuant strategies that reflect a determination of those strategies which in the aggregate are, or are not, appropriate for the Millennium Partners Funds based on, among other factors, our assessment of the characteristics of the strategies and the current risk and return profile applicable to the Millennium Partners Funds and such other considerations as we deem relevant. Other considerations for allocating WorldQuant strategies may include their simulated market impact (or lack thereof) on the Millennium Partners Funds. The allocation approach set forth in the Investment Allocation Policy and Procedures may result in WorldQuant strategies being preferentially allocated to the Millennium Partners Funds or other Client accounts over the WMA Funds and/or the Separate Accounts. Further, the strategies utilized for the benefit of a Client could have a market impact that negatively correlates with another Client’s returns and, if utilized for a Client, could potentially have improved (or detracted from) the overall returns of the Client. For example, the Millennium Partners Funds do not have turnover parameters and do have higher turnover rates than those currently expected for the WMA Funds and the Separate Accounts, which may have a negative impact on the returns of the WMA Funds and/or the Separate Accounts. The above allocation criteria may be changed from time to time in our sole discretion if we determine that such changes are appropriate in light of changes in circumstances or otherwise in accordance with the Investment Allocation Policy and Procedures. For example, to the extent we change the investment program of a Client, and in particular its risk and return profile for strategies developed by WorldQuant, these allocation criteria may be revised without prior notice to investors. Additionally, the approach to allocating strategies described above may change materially over time. Without limiting the generality of the foregoing, certain strategies may be utilized for Clients in proportions to be determined in accordance with the Investment Allocation Policy and Procedures. The determination at a given time not to allocate certain strategies to a Client is not an indication that strategies having similar attributes are not currently, or will not in the future be, utilized on behalf of such Client. As discussed herein, strategy allocations will be made based in large part on simulated results. Simulated performance of a strategy does not guarantee similar performance in production, which may be, and often is, materially different. While the - 46 -
Item 12: Brokerage practices Conflicts of interest
In selecting brokers, dealers and other counterparties to effect portfolio transactions for Clients and provide financing for such Client’s portfolio, we and our Portfolio Managers consider such factors as they deem appropriate under the circumstances, which may, and do, include one or more of the following: the ability to obtain timely execution and deliver timely execution reports; the responsiveness to the Firm’s orders; the reliability, reputation, integrity, and financial condition of the broker-dealer; the size and volume of the broker’s order flow; the ability to handle difficult trades, including block trades; the ability to find liquidity in the market while also minimizing market impact; research and other services provided to the Firm that are expected to enhance the Firm’s general portfolio management capabilities; other relationships between the Firm or a Client and the broker; the accommodation of special needs, including the broker’s willingness to enter into commission sharing arrangements/give-up agreements; and commission rates, fees or market maker’s commission equivalent (i.e., mark-downs and mark-ups). We do not have an obligation to obtain the lowest available commission cost. Accordingly, if we determine in good faith that the commissions charged by a broker or the prices charged by a dealer are reasonable in relation to the value of the brokerage and research products or services provided by such broker or dealer, a Client may pay commissions to such broker or prices to such dealer in an amount greater than another might charge. Subject to our duty to seek to obtain best execution, we have complete discretion in deciding what brokers, dealers and other counterparties Clients will use and in negotiating the rates of compensation Clients will pay to such brokers, dealers and other counterparties. In many instances that discretion is delegated to Portfolio Managers who make specific trading decisions, subject to oversight by Millennium. The Firm maintains policies and procedures to review the quality of executions, including periodic review by relevant personnel. From time to time, brokers (including prime brokers) and/or affiliates thereof engage in activities, including making investor introductions or acting as an investment adviser to prospective investors, or in a similar capacity, which result in capital being invested in the Feeder Funds or other products advised by the Firm. Without limiting the generality of the foregoing, brokers provide capital introduction and marketing assistance services, and our representatives from time to time speak at conferences and programs sponsored by the brokers, for investors interested in investing in private investment funds. Through such events, prospective investors in a Fund encounter our representatives. Certain of a Fund’s prime brokers (or their affiliates) also advise private funds or clients that make investments in a Fund or may facilitate such investments in other ways. Neither our Firm nor the Funds directly compensate any prime broker for engaging in such activities. However, the types of activities described above may influence us to some extent in selecting prime brokers and determining the extent to which a prime broker will be used. The Millennium Partners Funds utilize soft dollar arrangements, while currently other Funds and Separate Accounts do not. The disclosure below relates to the Millennium Partners Funds. With respect to soft dollar arrangements, the conflicts that typically give rise to concerns underlying the use of soft dollars do not generally exist for us, because the Millennium Partners Funds (and not our Firm) bears all of the expenses related to its own operation. Therefore, our use of soft dollars does not result in any expense shifting between our Firm, on the one hand, and the Millennium Partners Funds, on the other hand. However, Millennium Partners’ financial statements will be affected by soft dollar arrangements, as noted below. Soft dollar arrangements provide an incentive to select or recommend a broker-dealer based on an interest in receiving research or other products or services, rather than on receiving most favorable execution. Soft dollar arrangements may cause the Millennium Partners Funds to pay commissions (or markups or markdowns) higher than those charged by other broker-dealers in return for soft dollar benefits (known as paying-up). We use soft dollar benefits to service the Millennium Partners Funds. Portfolio Managers may also benefit from the use of soft dollars. We are not required to allocate soft dollar benefits among our Clients proportionately to the soft dollar credits the accounts of the Clients generate. Therefore, it is theoretically possible that a Client will benefit disproportionately from soft dollars relative to its contribution to the expenditure that generated them. If we advise additional Clients in the future, our Clients may experience this to an even greater degree. We have determined that the use of soft dollars will be limited to research and brokerage products and services that we believe meet the requirements of Section 28(e) of the Securities Exchange Act of 1934 (“Section 28(e)”), and the SEC interpretations thereof, in jurisdictions and transactions where Section 28(e) applies. This includes research and brokerage products and services paid for with soft dollars generated by the trading activity directed - 54 -
by our affiliated management companies. Although potentially outside the scope of Section 28(e), we have also adopted a policy to the effect that the requirements of Section 28(e) should generally be satisfied by our affiliated non-U.S. management companies in addition to any local requirements applicable to a particular management company with respect to the use of soft dollars. We generate soft dollars with commissions on securities transactions, and, in accordance with SEC interpretations, with markups, markdowns, commission equivalents or other fees paid to a dealer for executing a transaction. In addition, to the extent consistent with applicable regulatory requirements, soft dollars may be generated through futures transactions, certain principal transactions, non-U.S. transactions, or other transactions. Research products or services provided to the Millennium Partners Funds include research reports on particular industries and companies, economic surveys and analyses, recommendations as to specific securities, and relevant market data, as well as other products and services that provide assistance to us in the performance of their investment and trading decision-making responsibilities. Brokerage products or services provided to us may include message services used to transmit orders to brokers for execution, trading software used to route orders to market centers, software used to transmit orders to direct market access systems and short-term custody. Where a product or service obtained with soft dollars provides both research or brokerage and non-research or non-brokerage assistance (i.e., a “mixed use” item), we will make a reasonable allocation of the cost which is to be paid for with commission dollars. Consistent with Section 28(e), research products or services obtained with soft dollars generated by Millennium Partners may be used by Millennium to service one or more other Clients, including Clients that may not have paid for the soft dollar benefits. Millennium will seek to allocate the cost of the research products or services, including such items paid for using soft dollars, among the Millennium Partners Funds and other Clients in accordance with its Expense Allocation Policy and Procedures. A consequence of the use of soft dollar arrangements is that, under GAAP, items that would otherwise be characterized as expenses in the consolidated financial statements of Millennium Partners will instead be subsumed within commissions. As a result, line-item expenses will appear smaller than they would have had soft dollars not been utilized. It is possible that some expenses paid through the utilization of soft dollar arrangements might be greater than if the Millennium Partners Funds or the Firm had purchased the research or brokerage services in question directly or had produced them internally. In Europe, separate research charges may be assessed alongside Millennium Partners transactions and collected by Millennium Partners’ trading counterparties for the purpose of funding a research payment account controlled by Millennium. Such research charges are separate and independent of any commissions. The Firm’s Brokerage Committee oversees the Firm’s use of commissions and soft dollar arrangements, and its brokerdealer and counterparty relationships. The Brokerage Committee is responsible for: (1) reviewing the reasonableness of commissions and soft dollar usage throughout the Firm, (2) assessing the quality of services obtained from brokerdealer relationships generally, (3) implementing appropriate processes, reviews and procedures and (4) making appropriate recommendations to management concerning brokerage relationships and issues. We do not currently but may in the future elect to combine purchase or sale orders for securities on behalf of multiple Clients and allocate the securities or other assets so purchased or sold on an average price basis among the accounts or using another methodology that we consider equitable. We do not routinely recommend, request or require that Clients direct us to execute transactions through a specified broker, dealer or other counterparty. However, in accordance with the terms of the respective investment management agreement, a Separate Account Client may require that some or all of the applicable Separate Account’s transactions be executed with certain permitted brokers, dealers or other counterparties.
- 55 -
Item 14: Client referrals and other compensation Conflicts of interest
We generally do not receive an economic benefit from anyone other than our Clients for providing investment advice or other advisory services, although see Item 11 of this Brochure regarding outside activities of the Firm and certain of its affiliates. We may and currently do compensate certain persons who are not our supervised persons for referrals of investors to invest in certain Funds. We have entered into, and may in the future enter into additional, agreements with registered broker-dealers or other appropriately licensed or registered (to the extent legally required) persons providing for payment of a portion of the subscription amount or ongoing payments based on a percentage of the compensation we earn from certain Funds that are attributable to the interests of an investor in such Funds introduced by the persons. Any such fees are paid by the Firm (and not a Fund).
- 57 -
Item 9: Disciplinary information
On October 31, 2017, Millennium Management LLC (the “Millennium Respondent”) consented, without admitting or denying the findings therein, to the entry of an order issued by the SEC finding that on four occasions in 2012 it violated Rule 105 of Regulation M of the U.S. Securities Exchange Act of 1934 (“Rule 105”). (See SEC Release No. 34-81989.) In settlement of this matter, the Millennium Respondent agreed to pay a civil money penalty of $300,000, as well as disgorgement and prejudgment interest of $338,709.11, and to cease and desist from committing or causing any violations and any future violations of Rule 105. Additionally, as disclosed in detail on the Firm’s Form ADV Part 1, in four instances the Firm submitted notifications to the Swedish Financial Supervisory Authority (the “SFSA”) and in one instance the Firm submitted notification to the Financial Supervisory Authority of Norway (“Finanstilsynet”) later than the next-day filing deadline. In each instance, the delay in filing was due to inadvertent human error. The SFSA issued special fees in the Swedish matters totaling approximately $62,000 and Finanstilsynet imposed a violation penalty in the Norwegian matter of approximately $4,600. The Swedish fines became effective and were paid by the Firm in November 2019 and the Norwegian fine was imposed and paid by the Firm in January 2022. Further, as disclosed on the Firm’s Form ADV Part 1, the CME alleged that the Firm violated NYMEX Rules 432.Q. and 432.W. (act detrimental to exchange/supervision) with respect to sending two separate futures orders to a thirdparty FCM’s trading execution algorithm (which then placed multiple orders for the Firm on the futures exchange), which, in one case, resulted in a trading halt. Without admitting or denying the violations or factual findings, the Firm settled the matter in December 2022 and agreed to pay a fine of $90,000.
- 40 -
Item 13: Review of accounts
Funds The investment portfolios of the Funds are primarily managed by the Portfolio Managers. Generally, the Portfolio Managers are responsible for frequently reviewing the portion of the portfolio managed by them for consistency with the Firm’s policies. The Portfolio Managers are responsible to the head of the department for the strategy in which the Portfolio Managers trade, either directly or indirectly. In addition, various members of our management review the Funds’ portfolios and accounts on a regular basis. Reports that we generate for our internal use and for the benefit of the Funds typically contain portfolio breakdowns and performance. The reports are provided no less frequently than monthly. Separate Accounts The frequency of the review of Separate Accounts, the nature of the review, and the factors which may trigger reviews can vary widely depending on the Client’s investment objectives and circumstances and the complexity, portfolio structure and size of an account. The type and frequency of reporting in respect of a Separate Account will vary based on the terms set forth in the Client’s investment management agreement.
- 56 -
Item 15: Custody
We serve as general partner to the Funds for which we provide investment advisory services. Accordingly, we are deemed to have custody of Client funds and securities for such Funds. However, we do not send quarterly (or more frequent) statements to the Funds. We generally do not maintain custody of Client funds or securities for Separate Accounts because we do not have possession or authority to obtain possession of such funds or securities. Client funds and securities for Separate Accounts are held on the Client’s behalf with third‐party custodians. Clients should review any statements received from us or a custodian carefully, and to the extent they receive statements from both us and a custodian, they are urged to compare such statements carefully.
- 58 -
Item 16: Investment discretion
We have discretionary authority to manage securities accounts on behalf of our Clients. This authority is established through a limited partnership agreement, an investment management agreement, or other contract. With respect to the Funds, there are no substantive limits on our discretionary authority. We may agree with a Separate Account Client in writing to impose certain investment guidelines or restrictions, which may limit the types of securities or other instruments in which we are authorized to trade on behalf of its account.
- 59 -
Item 17: Voting client securities
We have authority to vote Client securities with respect to the Funds. We generally do not vote proxies on behalf of Separate Account Clients, and we generally do not provide proxy or corporate action recommendations to Clients who have not granted us voting authority over their securities. It is generally the responsibility of the Separate Account Clients to instruct the relevant custodian to mail proxy materials directly to such Client. We may agree otherwise with a Separate Account Client in their separately managed account agreement. Where we have authority to vote proxies, as a general matter, we do not authorize individual Portfolio Managers to make proxy voting decisions without permission. In situations where a Portfolio Manager believes it is useful to vote a proxy, we will vote securities on behalf of a Fund upon the request of a Portfolio Manager who has discretion over the relevant securities, provided that the CLEO Committee (or its designee), or any successor body thereto, determines that the requested vote is in such Fund’s best interests and approves the requested vote. Any conflicts, including where two or more Portfolio Managers seek permission to vote a proxy but have differing views concerning how the proxy should be voted, are considered and resolved, as appropriate, by the CLEO Committee or any successor body thereto. Clients may obtain information from us about how we voted their securities by contacting us at (212) 8414100. Clients may obtain a copy of our proxy voting policies and procedures upon request.
- 60 -
Item 18: Financial information
We are not aware of any financial condition that is reasonably likely to impair our ability to meet contractual commitments to the Funds, and have not been the subject of a bankruptcy petition at any time during the past 10 years.
- 61 -
Filings
24 filings to the SEC since October 2021: 1 large holders, 23 other. The latest 20:
- Aug 27, 2026N-PX EDGAR
- Aug 14, 202613F-HR EDGAR
- May 15, 202613F-HR EDGAR
- Feb 17, 202613F-HR EDGAR
- Nov 14, 202513F-HR EDGAR
- Aug 29, 2025N-PX EDGAR
- Aug 14, 202513F-HR EDGAR
- May 15, 202513F-HR EDGAR
- Feb 14, 202513F-HR EDGAR
- Nov 14, 202413F-HR EDGAR
- Oct 28, 2024SC 13G/A EDGAR
- Aug 29, 2024N-PX EDGAR
- Aug 14, 202413F-HR EDGAR
- May 15, 202413F-HR EDGAR
- Feb 14, 202413F-HR EDGAR
- Nov 14, 202313F-HR EDGAR
- Aug 14, 202313F-HR EDGAR
- May 15, 202313F-HR EDGAR
- Feb 14, 202313F-HR EDGAR
- Nov 14, 202213F-HR EDGAR
The 24 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
1 such filings since October 2021:
- Oct 28, 2024SC 13G/A
Stakes it holds
MILLENNIUM MANAGEMENT LLC has told the SEC it owns more than 5% of 305 companies, latest first (Schedules 13D and 13G).
- TENAX THERAPEUTICS, INC.SCHEDULE 13G/A May 20, 2026 to Oct 15, 20264
- CAPRICOR THERAPEUTICS, INC.SCHEDULE 13G/A Aug 19, 2026 to Oct 14, 20265
- AmerescoSCHEDULE 13G/A Jul 22, 2026 to Oct 13, 20266
- WW InternationalSCHEDULE 13G/A Mar 23, 2023 to Oct 13, 20267
- iRhythm Holdings, Inc.SCHEDULE 13G/A Mar 23, 2026 to Oct 13, 20268
- Vanda Pharmaceuticals Inc.SCHEDULE 13G/A Jul 1, 2025 to Oct 9, 20269
- vTv Therapeutics Inc.SCHEDULE 13G/A Mar 27, 2026 to Oct 8, 202610
- DYCOM INDUSTRIES INCSCHEDULE 13G Aug 15, 2023 to Oct 7, 202611
- T1 EnergySCHEDULE 13G/A Aug 19, 2026 to Oct 7, 202612
- SweetgreenSCHEDULE 13G/A Sep 29, 2026 to Oct 6, 202613
- AMERISAFE INCSCHEDULE 13G Sep 30, 202614
- IndiviorSCHEDULE 13G Dec 22, 2025 to Sep 30, 202615
- Maravai LifeSciences Holdings, Inc.SCHEDULE 13G Oct 26, 2023 to Sep 29, 202616
- Beyond MeatSCHEDULE 13G Sep 28, 202617
- Haymaker Acquisition Corp VSCHEDULE 13G Sep 23, 202618
- Lincoln International, Inc.SCHEDULE 13G Sep 18, 202619
- First Horizon National CorporationSCHEDULE 13G Sep 9, 202620
- Catalyst Acquisition Corp.SCHEDULE 13G/A Aug 4, 2026 to Aug 24, 202621
- GrouponSCHEDULE 13G Aug 17, 202622
- Enhanced Group Inc.SCHEDULE 13G/A Mar 11, 2026 to Aug 14, 202623
- Factorial Energy Inc.SCHEDULE 13G/A May 7, 2026 to Aug 14, 202624
- Perspective Therapeutics, Inc.SCHEDULE 13G/A Jun 30, 2026 to Aug 13, 202625
- Ralliant CorpSCHEDULE 13G Aug 13, 202626
- DXC TechnologySCHEDULE 13G/A Jun 24, 2026 to Aug 12, 202627
- Irenic Acquisition Corp.SCHEDULE 13G/A May 5, 2026 to Aug 12, 202628
- Wix.comSCHEDULE 13G/A Apr 2, 2026 to Aug 12, 202629
- Quantum Leap Acquisition CorpSCHEDULE 13G/A May 7, 2026 to Aug 11, 202630
- InvescoSCHEDULE 13G/A Oct 21, 2025 to Aug 10, 202631
- OMNICELL, INC.SCHEDULE 13G/A Apr 1, 2026 to Aug 10, 202632
- Trex Company, Inc.SCHEDULE 13G Aug 7, 202633
All 305 companies
- Cytek Biosciences, Inc.SCHEDULE 13G/A Apr 9, 2026 to Aug 6, 202634
- SUPERNUS PHARMACEUTICALS, INC.SCHEDULE 13G/A Feb 2, 2026 to Aug 6, 202635
- RxSight, Inc.SCHEDULE 13G/A Jul 15, 2025 to Aug 4, 202636
- Churchill Capital Corp XISCHEDULE 13G/A Dec 23, 2025 to Jul 31, 202637
- StepStone Group Inc.SCHEDULE 13G/A Jun 20, 2024 to Jul 31, 202638
- Apollo Commercial Real Estate Finance, Inc.SCHEDULE 13G Jul 30, 202639
- PHIBRO ANIMAL HEALTH CORPSCHEDULE 13G Jul 30, 202640
- Cabaletta Bio, Inc.SCHEDULE 13G/A Feb 18, 2026 to Jul 23, 202641
- Boston Beer CompanySCHEDULE 13G Jul 22, 202642
- ServiceTitanSCHEDULE 13G/A May 26, 2026 to Jul 21, 202643
- MACROGENICS INCSCHEDULE 13G/A Sep 2, 2022 to Jul 20, 202644
- Phathom Pharmaceuticals, Inc.SCHEDULE 13G/A Aug 13, 2025 to Jul 20, 202645
- Contineum Therapeutics, Inc.SCHEDULE 13G/A Apr 17, 2026 to Jul 17, 202646
- Forte Biosciences, Inc.SCHEDULE 13G/A Jun 8, 2026 to Jul 16, 202647
- Bleichroeder Acquisition Corp. IISCHEDULE 13G/A Jan 14, 2026 to Jul 15, 202648
- BANC OF CALIFORNIA, INC.SCHEDULE 13G/A Mar 24, 2026 to Jul 14, 202649
- Silverback TherapeuticsSCHEDULE 13G/A Mar 24, 2026 to Jul 14, 202650
- Elme CommunitiesSCHEDULE 13G/A Jan 13, 2026 to Jul 13, 202651
- Byrna Technologies Inc.SCHEDULE 13G/A Apr 16, 2026 to Jul 10, 202652
- HMH Holding IncSCHEDULE 13G/A Apr 8, 2026 to Jul 9, 202653
- National Healthcare Properties, Inc.SCHEDULE 13G/A Apr 29, 2026 to Jul 9, 202654
- Ares Acquisition Corp IIISCHEDULE 13G Jul 7, 202655
- Proteon TherapeuticsSCHEDULE 13G/A Mar 2, 2026 to Jul 7, 202656
- Avalo Therapeutics, Inc.SCHEDULE 13G/A Feb 3, 2026 to Jul 6, 202657
- Kensington Capital Acquisition Corp. VISCHEDULE 13G/A Mar 11, 2026 to Jul 6, 202658
- BELLRING BRANDS, INC.SCHEDULE 13G Jun 29, 202659
- LENZ Therapeutics, Inc.SCHEDULE 13G Jun 26, 202660
- Xanadu Quantum Technologies LtdSCHEDULE 13G Jun 25, 202661
- RELMADA THERAPEUTICS, INC.SCHEDULE 13G Jun 22, 202662
- Snow Rothschild Acquisition Corp.SCHEDULE 13G Jun 16, 202663
- Tonix PharmaceuticalsSCHEDULE 13G Jun 15, 202664
- Long Table Growth Corp.SCHEDULE 13G Jun 9, 202665
- Faeth Therapeutics, Inc.SCHEDULE 13G/A May 15, 2026 to Jun 3, 202666
- Berto Acquisition Corp. IISCHEDULE 13G May 21, 202667
- Optimum CommunicationsSCHEDULE 13G/A Jun 20, 2025 to May 14, 202668
- NeoGenomicsSCHEDULE 13G/A Dec 2, 2025 to May 13, 202669
- YextSCHEDULE 13G/A Mar 16, 2026 to May 11, 202670
- Karbon Capital Partners Corp.SCHEDULE 13G/A Dec 16, 2025 to May 8, 202671
- General Catalyst Global Resilience Merger Corp.SCHEDULE 13G May 6, 202672
- Churchill Capital Corp XIISCHEDULE 13G May 5, 202673
- Immix Biopharma, Inc.SCHEDULE 13G/A Mar 20, 2026 to May 4, 202674
- KalVista Pharmaceuticals, Inc.SCHEDULE 13G/A Nov 10, 2025 to May 1, 202675
- SAB Biotherapeutics, Inc.SCHEDULE 13G May 1, 202676
- Zafgen (United States)SCHEDULE 13G/A Jun 17, 2025 to Apr 30, 202677
- ALX ONCOLOGY HOLDINGS INCSCHEDULE 13G/A Aug 13, 2024 to Apr 28, 202678
- ConstelliumSCHEDULE 13G/A May 30, 2025 to Apr 24, 202679
- General Purpose Acquisition Corp.SCHEDULE 13G/A Dec 8, 2025 to Apr 23, 202680
- Helus Pharma Inc.SCHEDULE 13G/A Mar 26, 2026 to Apr 22, 202681
- EverQuoteSCHEDULE 13G/A Feb 27, 2026 to Apr 21, 202682
- Sutro BiopharmaSCHEDULE 13G/A Jul 8, 2022 to Apr 21, 202683
- OcugenSCHEDULE 13G Apr 14, 202684
- PennyMac Financial Services, Inc.SCHEDULE 13G Apr 1, 202685
- SUMA Acquisition CorpSCHEDULE 13G Mar 18, 202686
- Cohen Circle Acquisition Corp. IISCHEDULE 13G/A Feb 4, 2026 to Mar 10, 202687
- NETSTREIT Corp.SCHEDULE 13G Sep 8, 2022 to Feb 20, 202688
- Proem Acquisition Corp. ISCHEDULE 13G Feb 20, 202689
- Vermilion EnergySCHEDULE 13G/A Mar 3, 2025 to Feb 13, 202690
- Dauch CorpSCHEDULE 13G/A Jun 16, 2025 to Feb 6, 202691
- Fulgent GeneticsSCHEDULE 13G/A Jan 8, 2025 to Feb 4, 202692
- GigCapital9 Corp.SCHEDULE 13G Feb 3, 202693
- Praetorian Acquisition Corp.SCHEDULE 13G Jan 30, 202694
- Pyrophyte Acquisition Corp. IISCHEDULE 13G/A Jul 23, 2025 to Jan 29, 202695
- Highview Merger Corp.SCHEDULE 13G/A Aug 14, 2025 to Jan 27, 202696
- Braze, Inc.SCHEDULE 13G Jan 21, 202697
- ANAPTYSBIO, INCSCHEDULE 13G/A Sep 23, 2025 to Jan 16, 202698
- Strive, Inc.SCHEDULE 13G/A Sep 18, 2025 to Jan 15, 202699
- LoanDepotSCHEDULE 13G/A Oct 7, 2025 to Jan 7, 2026100
- FrontView REIT, Inc.SCHEDULE 13G/A Oct 10, 2024 to Jan 6, 2026101
- Silicon Valley Acquisition Corp.SCHEDULE 13G Dec 31, 2025102
- ITHAX Acquisition Corp IIISCHEDULE 13G Dec 18, 2025103
- TransAlta CorporationSCHEDULE 13G/A Feb 25, 2025 to Nov 14, 2025104
- Ardelyx (United States)SCHEDULE 13G/A Dec 2, 2022 to Oct 28, 2025105
- AimcoSCHEDULE 13G/A Jan 7, 2025 to Oct 24, 2025106
- Beta Bionics, Inc.SCHEDULE 13G/A Sep 19, 2025 to Oct 16, 2025107
- Hain Celestial GroupSCHEDULE 13G/A Mar 26, 2025 to Oct 15, 2025108
- Pyxis Oncology, Inc.SCHEDULE 13G/A Jul 1, 2025 to Oct 14, 2025109
- Zentalis Pharmaceuticals, Inc.SCHEDULE 13G/A Feb 4, 2025 to Oct 14, 2025110
- Murphy USASCHEDULE 13G Aug 29, 2025111
- 10X GenomicsSCHEDULE 13G/A Apr 4, 2025 to Aug 12, 2025112
- ChemoursSCHEDULE 13G/A Jun 10, 2025 to Aug 8, 2025113
- EVgo Inc.SCHEDULE 13G/A Mar 20, 2025 to Jul 31, 2025114
- Camping WorldSCHEDULE 13G/A Feb 13, 2025 to Jul 28, 2025115
- Aclaris Therapeutics, Inc.SCHEDULE 13G/A Dec 11, 2023 to Jul 24, 2025116
- Dine Brands GlobalSCHEDULE 13G/A May 9, 2025 to Jul 24, 2025117
- Solaris Energy Infrastructure, Inc.SCHEDULE 13G/A May 8, 2025 to Jul 21, 2025118
- LIGHTBRIDGE CorpSCHEDULE 13G/A Jun 20, 2025 to Jul 18, 2025119
- Oportun Financial CorpSCHEDULE 13G/A Mar 19, 2025 to Jul 18, 2025120
- Bold Eagle Acquisition Corp.SCHEDULE 13G/A Oct 30, 2024 to Jul 16, 2025121
- Oaktree Acquisition Corp. III Life SciencesSCHEDULE 13G/A Oct 30, 2024 to Jul 15, 2025122
- SmartStop Self Storage REIT, Inc.SCHEDULE 13G/A May 27, 2025 to Jul 14, 2025123
- TPGSCHEDULE 13G Jun 23, 2025124
- Janus Henderson Group Ltd.SCHEDULE 13G May 16, 2025125
- Kala Pharmaceuticals (United States)SCHEDULE 13G/A Feb 16, 2024 to May 12, 2025126
- Gores Holdings X, Inc. / CISCHEDULE 13G May 8, 2025127
- Verve Therapeutics, Inc.SCHEDULE 13G Jun 27, 2024 to Apr 29, 2025128
- Quanterix (United States)SCHEDULE 13G/A Sep 29, 2023 to Apr 23, 2025129
- Pacira BioSciences, Inc.SCHEDULE 13G/A Jan 15, 2025 to Apr 21, 2025130
- Hudson Pacific PropertiesSCHEDULE 13G/A Dec 26, 2024 to Apr 17, 2025131
- Titan Acquisition Corp.SCHEDULE 13G Apr 16, 2025132
- ANGIODYNAMICS INCSCHEDULE 13G/A Dec 15, 2022 to Apr 14, 2025133
- ANI PHARMACEUTICALS INCSCHEDULE 13G/A Jan 21, 2025 to Apr 10, 2025134
- Pacific BiosciencesSCHEDULE 13G/A Nov 8, 2024 to Apr 9, 2025135
- Utz BrandsSCHEDULE 13G/A Jan 23, 2025 to Apr 7, 2025136
- Puma BiotechnologySCHEDULE 13G/A Jan 14, 2022 to Feb 3, 2025137
- BioAtlaSCHEDULE 13G/A Aug 7, 2024 to Jan 24, 2025138
- GoodRxSCHEDULE 13G/A Dec 16, 2022 to Jan 24, 2025139
- AMC Global MediaSCHEDULE 13G/A Sep 30, 2024 to Jan 16, 2025140
- American Healthcare REIT, Inc.SCHEDULE 13G/A Mar 4, 2024 to Jan 14, 2025141
- Onterris, Inc.SC 13G Dec 17, 2024142
- Outset Medical, Inc.SC 13G/A Aug 23, 2024 to Nov 12, 2024143
- Semtech CorporationSC 13G/A Apr 23, 2024 to Nov 6, 2024144
- VERU INC.SC 13G/A Apr 24, 2024 to Nov 4, 2024145
- Solid Biosciences Inc.SC 13G/A Jun 5, 2024 to Nov 1, 2024146
- Mobileye GlobalSC 13G/A Jan 9, 2024 to Oct 31, 2024147
- ModivCare IncSC 13G/A Apr 12, 2024 to Oct 28, 2024148
- Standard BioTools Inc.SC 13G/A Feb 26, 2024 to Oct 21, 2024149
- ENANTA PHARMACEUTICALS INCSC 13G/A Nov 16, 2023 to Oct 17, 2024150
- Esperion TherapeuticsSC 13G/A Jan 20, 2023 to Oct 17, 2024151
- Altimmune, Inc.SC 13G/A Mar 5, 2024 to Oct 16, 2024152
- Bridge Investment Group Holdings Inc.SC 13G/A Dec 7, 2023 to Oct 15, 2024153
- Corbus PharmaceuticalsSC 13G/A Feb 28, 2024 to Oct 15, 2024154
- Adicet Bio, Inc.SC 13G/A Feb 27, 2024 to Oct 8, 2024155
- Sila Realty Trust, Inc.SC 13G Sep 24, 2024156
- ADMA Biologics (United States)SC 13G Jun 28, 2022 to Sep 23, 2024157
- MedifastSC 13G Jul 1, 2024158
- TidewaterSC 13G Jun 25, 2024159
- Churchill Capital Corp IX/CaymanSC 13G May 9, 2024160
- RubrikSC 13G May 8, 2024161
- American National Group Inc.SC 13G May 7, 2024162
- Inari Medical, Inc.SC 13G Apr 3, 2024163
- Sumisho Air LeaseSC 13G Mar 22, 2024164
- MGE Energy, Inc.SC 13G Mar 21, 2024165
- BoxSC 13G Mar 20, 2024166
- BGC PartnersSC 13G Mar 19, 2024167
- Myriad GeneticsSC 13G Mar 18, 2024168
- Growth for Good Acquisition CorpSC 13G/A Apr 4, 2022 to Feb 12, 2024169
- Crescera Capital Acquisition Corp.SC 13G/A Apr 20, 2022 to Feb 9, 2024170
- Tristar Acquisition I Corp.SC 13G/A Apr 13, 2022 to Feb 9, 2024171
- Perception Capital Corp. IVSC 13G/A Apr 14, 2022 to Feb 7, 2024172
- Project Energy Reimagined Acquisition Corp.SC 13G/A Mar 10, 2022 to Feb 7, 2024173
- IX Acquisition Corp.SC 13G/A Apr 11, 2022 to Feb 6, 2024174
- Oric Pharmaceuticals, Inc.SC 13G/A Jan 20, 2023 to Feb 6, 2024175
- AleAnna, Inc.SC 13G/A Apr 13, 2022 to Feb 5, 2024176
- DIGIASIA CORP.SC 13G/A Apr 4, 2022 to Feb 2, 2024177
- Global Technology Acquisition Corp. ISC 13G/A Apr 14, 2022 to Feb 2, 2024178
- 2seventy bio, Inc.SC 13G/A May 15, 2023 to Feb 1, 2024179
- Generation Asia I Acquisition LtdSC 13G/A Apr 21, 2022 to Jan 31, 2024180
- Screaming Eagle Acquisition Corp.SC 13G/A Jan 11, 2022 to Jan 30, 2024181
- SURMODICS INCSC 13G/A Mar 20, 2023 to Jan 29, 2024182
- DIVERSIFIED HEALTHCARE TRUSTSC 13G/A Dec 22, 2022 to Jan 26, 2024183
- eHealthInsuranceSC 13G/A Sep 26, 2022 to Jan 25, 2024184
- EBIX INCSC 13G/A Nov 2, 2023 to Jan 23, 2024185
- Kezar Life Sciences, Inc.SC 13G/A Jun 23, 2022 to Jan 22, 2024186
- NextCure, Inc.SC 13G/A Jan 24, 2023 to Jan 19, 2024187
- Emergent BioSolutionsSC 13G/A Sep 7, 2023 to Jan 18, 2024188
- AMERICAN VANGUARD CORPSC 13G/A Oct 11, 2023 to Jan 16, 2024189
- Designer BrandsSC 13G/A Jul 5, 2023 to Jan 16, 2024190
- Inozyme Pharma, Inc.SC 13G/A May 31, 2023 to Jan 16, 2024191
- MOTORCAR PARTS OF AMERICA INCSC 13G/A Jun 28, 2023 to Jan 16, 2024192
- X4 Pharmaceuticals, IncSC 13G/A Jun 16, 2023 to Jan 16, 2024193
- JOINT CorpSC 13G/A Jan 13, 2023 to Jan 12, 2024194
- Viking TherapeuticsSC 13G/A Jan 3, 2023 to Jan 12, 2024195
- scPharmaceuticals (United States)SC 13G/A Mar 13, 2023 to Jan 12, 2024196
- Gossamer Bio, Inc.SC 13G/A Dec 20, 2022 to Jan 11, 2024197
- LendingTreeSC 13G/A Oct 4, 2023 to Jan 10, 2024198
- iTeos Therapeutics, Inc.SC 13G/A Oct 24, 2023 to Jan 9, 2024199
- Rush EnterprisesSC 13G Jan 2, 2024200
- Triton InternationalSC 13G Oct 10, 2023201
- UNIVERSAL INSURANCE HOLDINGS, INC.SC 13G Sep 21, 2023202
- Premier, Inc.SC 13G Sep 19, 2023203
- C4 Therapeutics (United States)SC 13G Jul 25, 2023204
- KYNTRA BIO, INC.SC 13G Jul 19, 2023205
- Terns Pharmaceuticals, Inc.SC 13G Jun 27, 2023206
- Granite Point Mortgage Trust Inc.SC 13G May 22, 2023207
- PlayAGS, Inc.SC 13G/A Apr 24, 2023 to May 10, 2023208
- Evolus, Inc.SC 13G/A Feb 15, 2023 to May 9, 2023209
- Asure SoftwareSC 13G May 5, 2023210
- Build-A-Bear WorkshopSC 13G Apr 11, 2023211
- AMC TheatresSC 13G Apr 5, 2023212
- Fate TherapeuticsSC 13G Mar 22, 2023213
- Golar LNGSC 13G Mar 16, 2023214
- Rigetti ComputingSC 13G/A Jan 13, 2022 to Feb 10, 2023215
- Disruptive Acquisition Corp ISC 13G/A Apr 18, 2022 to Feb 9, 2023216
- Highland Transcend Partners I Corp.SC 13G/A Apr 12, 2022 to Feb 9, 2023217
- MDH Acquisition Corp.SC 13G/A Apr 11, 2022 to Feb 9, 2023218
- Powered BrandsSC 13G/A Apr 18, 2022 to Feb 9, 2023219
- Aerojet Rocketdyne HoldingsSC 13G/A Mar 18, 2022 to Feb 8, 2023220
- Nogin, Inc.SC 13G/A Apr 11, 2022 to Feb 8, 2023221
- Sports Ventures Acquisition Corp.SC 13G/A Mar 1, 2022 to Feb 8, 2023222
- Akili, Inc.SC 13G/A Feb 15, 2022 to Feb 7, 2023223
- Cano Health, Inc.SC 13G/A Mar 7, 2022 to Feb 7, 2023224
- GrindrSC 13G/A Mar 24, 2022 to Feb 7, 2023225
- Diebold NixdorfSC 13G/A Dec 23, 2022 to Feb 6, 2023226
- North Mountain Merger Corp.SC 13G/A Jan 12, 2022 to Feb 6, 2023227
- Iron Spark I Inc.SC 13G/A Jul 22, 2022 to Feb 3, 2023228
- Social Capital Hedosophia Holdings Corp. IVSC 13G/A Feb 4, 2022 to Feb 3, 2023229
- Bright Lights Acquisition Corp.SC 13G/A Aug 23, 2022 to Feb 1, 2023230
- Big Sky Growth Partners, Inc.SC 13G/A Jul 25, 2022 to Jan 31, 2023231
- Population Health Investment Co., Inc.SC 13G/A Apr 22, 2022 to Jan 30, 2023232
- Brand Engagement Network Inc.SC 13G/A Mar 23, 2022 to Jan 27, 2023233
- Roth CH Acquisition Co.SC 13G Jan 27, 2023234
- Silver Spike Acquisition Corp IISC 13G/A Jun 28, 2022 to Jan 27, 2023235
- TCV Acquisition Corp.SC 13G/A Apr 7, 2022 to Jan 27, 2023236
- VEEA INC.SC 13G/A Apr 6, 2022 to Jan 27, 2023237
- InvenTrust Properties Corp.SC 13G/A May 24, 2022 to Jan 26, 2023238
- Keyarch Acquisition CorpSC 13G/A Mar 25, 2022 to Jan 26, 2023239
- Valor Latitude Acquisition Corp.SC 13G/A Apr 12, 2022 to Jan 26, 2023240
- Viridian Therapeutics, Inc.\DESC 13G/A May 31, 2022 to Jan 26, 2023241
- Talon 1 Acquisition CorpSC 13G/A Apr 14, 2022 to Jan 25, 2023242
- Vector Acquisition Corp IISC 13G/A Apr 13, 2022 to Jan 25, 2023243
- ViewRaySC 13G/A Mar 9, 2022 to Jan 25, 2023244
- Spring Valley Acquisition Corp. IISC 13G/A Oct 18, 2022 to Jan 24, 2023245
- Thunder Bridge Capital Partners IV, Inc.SC 13G/A Jul 25, 2022 to Jan 24, 2023246
- Trine II Acquisition Corp.SC 13G/A Oct 19, 2022 to Jan 24, 2023247
- BlueRiver Acquisition Corp.SC 13G/A Apr 6, 2022 to Jan 23, 2023248
- SKYDECK ACQUISITION CORP.SC 13G/A Apr 13, 2022 to Jan 23, 2023249
- SPORTSMAN'S WAREHOUSE HOLDINGS, INC.SC 13G/A Jan 14, 2022 to Jan 23, 2023250
- TACTILE SYSTEMS TECHNOLOGY INCSC 13G/A Jun 23, 2022 to Jan 23, 2023251
- Thrive Acquisition CorpSC 13G/A Mar 3, 2022 to Jan 23, 2023252
- Mersana Therapeutics (United States)SC 13G/A Feb 17, 2022 to Jan 19, 2023253
- Neurogene Inc.SC 13G/A Jul 7, 2022 to Jan 19, 2023254
- Phillips Edison & Company, Inc.SC 13G/A Mar 11, 2022 to Jan 19, 2023255
- Mason Industrial Technology, Inc.SC 13G/A Oct 20, 2022 to Jan 18, 2023256
- Rose Hill Acquisition CorpSC 13G/A Apr 20, 2022 to Jan 18, 2023257
- Spectaire Holdings Inc.SC 13G/A Feb 25, 2022 to Jan 18, 2023258
- CXApp Inc.SC 13G/A Apr 21, 2022 to Jan 17, 2023259
- Liberty TripAdvisor Holdings, Inc.SC 13G/A Jun 29, 2022 to Jan 17, 2023260
- M3-Brigade Acquisition II Corp.SC 13G/A Feb 16, 2022 to Jan 17, 2023261
- Minority Equality Opportunities Acquisition Inc.SC 13G/A Apr 12, 2022 to Jan 17, 2023262
- Health Catalyst, Inc.SC 13G/A Aug 30, 2022 to Jan 13, 2023263
- INDEPENDENCE REALTY TRUST, INC.SC 13G/A Mar 14, 2022 to Jan 13, 2023264
- Intercept PharmaceuticalsSC 13G/A Aug 18, 2022 to Jan 13, 2023265
- Bluescape Opportunities Acquisition Corp.SC 13G/A Apr 12, 2022 to Jan 12, 2023266
- GoGreen Investments CorpSC 13G/A Mar 2, 2022 to Jan 12, 2023267
- bluebird bioSC 13G/A Aug 1, 2022 to Jan 12, 2023268
- Apollo Strategic Growth Capital IISC 13G/A Oct 28, 2022 to Jan 11, 2023269
- BIOLIFE SOLUTIONS INCSC 13G/A Jun 22, 2022 to Jan 11, 2023270
- LanzaTech Global, Inc.SC 13G/A Mar 16, 2022 to Jan 11, 2023271
- Allakos Inc.SC 13G/A Jul 29, 2022 to Jan 10, 2023272
- Zeo Energy Corp.SC 13G/A Apr 13, 2022 to Jan 10, 2023273
- Anthemis Digital Acquisitions I CorpSC 13G/A Apr 5, 2022 to Jan 9, 2023274
- Bridgetown Holdings LtdSC 13G/A Apr 11, 2022 to Jan 9, 2023275
- CTI BioPharmaSC 13G/A Jun 13, 2022 to Jan 9, 2023276
- QT IMAGING HOLDINGS, INC.SC 13G/A Jul 6, 2022 to Jan 9, 2023277
- AbioMedSC 13G Dec 29, 2022278
- Silvergate Capital CorpSC 13G Dec 21, 2022279
- Flagstar BankSC 13G Dec 6, 2022280
- BAYTEX ENERGY USA, INC.SC 13G Nov 28, 2022281
- RIGEL PHARMACEUTICALS INCSC 13G Sep 22, 2022282
- Amylyx PharmaceuticalsSC 13G Sep 21, 2022283
- Outfront MediaSC 13G Sep 20, 2022284
- Tufin Software Technologies Ltd.SC 13G Aug 31, 2022285
- Endo International plcSC 13G Jun 27, 2022 to Aug 29, 2022286
- VonageSC 13G Jul 26, 2022287
- Vertex Energy Inc.SC 13G Jun 27, 2022288
- Vaalco EnergySC 13G Jun 22, 2022289
- Franklin BSP Realty Trust, Inc.SC 13G Jun 21, 2022290
- Hilltop Holdings Inc.SC 13G Jun 3, 2022291
- TriState Capital Holdings, Inc.SC 13G Jun 3, 2022292
- LibitySC 13G May 17, 2022293
- Chenghe Acquisition Co.SC 13G May 4, 2022294
- Global Synergy Acquisition Corp.SC 13G Apr 12, 2022295
- Macondray Capital Acquisition Corp. ISC 13G Apr 12, 2022296
- Trepont Acquisition Corp ISC 13G Apr 11, 2022297
- People's United FinancialSC 13G Apr 8, 2022298
- Black Spade Acquisition CoSC 13G Apr 5, 2022299
- Cascade Acquisition CorpSC 13G Apr 4, 2022300
- Metals Acquisition CorpSC 13G Mar 22, 2022301
- MONMOUTH REAL ESTATE INVESTMENT CORPSC 13G Mar 4, 2022302
- Aspire-Lakewood Holdings, Inc.SC 13G Feb 28, 2022303
- Oaktree Acquisition Corp. IISC 13G Feb 16, 2022304
- Spectrum PharmaceuticalsSC 13G Feb 10, 2022305
- ZymeworksSC 13G Feb 10, 2022306
- Hostess BrandsSC 13G Feb 4, 2022307
- Queen's Gambit Growth CapitalSC 13G Jan 20, 2022308
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- 207
- 208
- 209
- 210
- 211
- 212
- 213
- 214
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 260
- 261
- 262
- 263
- 264
- 265
- 266
- 267
- 268
- 269
- 270
- 271
- 272
- 273
- 274
- 275
- 276
- 277
- 278
- 279
- 280
- 281
- 282
- 283
- 284
- 285
- 286
- 287
- 288
- 289
- 290
- 291
- 292
- 293
- 294
- 295
- 296
- 297
- 298
- 299
- 300
- 301
- 302
- 303
- 304
- 305
- 306
- 307
- 308